Highlight
– A Bayesian network meta-analysis of nine phase 3 trials (n=6,425) assessed time to deterioration in patient-reported health-related quality of life (HR-QoL) across first-line systemic therapies for unresectable or advanced hepatocellular carcinoma (HCC).
– Atezolizumab plus bevacizumab ranked highest by SUCRA for preservation of global health/QoL and several HCC-specific symptoms; when integrated with overall survival, it provided the best combined profile across evaluated items.
